Oregon will receive $10.1 million as part of a new national settlement with eight pharmaceutical companies accused of contributing to the opioid crisis.
The agreement, announced Monday, is part of a $720 million multi-state deal involving drug manufacturers Mylan, Hikma, Amneal, Apotex, Indivior, Sun, Alvogen, and Zydus.
This latest payout increases Oregon’s total opioid-related settlement funds to over $700 million since July 2021. That includes a $66 million deal finalized last year with Purdue Pharma and the Sackler family.
According to the Oregon Department of Justice, 45% of the new funds will go to the state’s opioid settlement fund, while the remaining 55% will be directed toward prevention, treatment, and recovery efforts in local communities. Funds will be distributed through 2038 under the guidance of the state’s Settlement Prevention, Treatment and Recovery Board.
Oregon Attorney General Dan Rayfield emphasized the importance of accountability.
“No amount of money can rewind the clock, but this money will allow us to continue building a future free from this crisis by investing in drug treatment, prevention, and recovery support across our state,” Rayfield said in a statement.
The settlement is part of a joint effort involving nine states: Oregon, California, Colorado, Illinois, New York, North Carolina, Tennessee, Utah, and Virginia.
These funds are expected to support addiction services, reduce overdose deaths, and strengthen long-term recovery programs, especially in communities hardest hit by opioid misuse.
Related topics:
Scientists Explore How to Keep the Aging Brain Sharp
Study Confirms Diet, Not Inactivity, Drives Obesity Epidemic
